HSP90B2P and neoplasm: Treatment of CTLs engineered to target HSP27 and HSP90 peptides effectively decreased tumor growth in a mouse model with myeloma xenograft and stimulation of peripheral blood mononuclear cells (PBMC), resulting specifically in the generation of HSP peptide CTL [105].